Attached files
| file | filename |
|---|---|
| EX-10.1 - EXHIBIT 10.1 - PROGENICS PHARMACEUTICALS INC | ex10_117jun2013.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) June 12, 2013
Progenics Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
000-23143
|
|
13-3379479
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
|
|
777 Old Saw Mill River Road, Tarrytown, New York
|
|
10591
|
||
|
(Address of principal executive offices)
|
|
(Zip Code)
|
||
|
Registrant's telephone number, including area code (914) 789-2800
|
||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
(e) As previously reported in the proxy materials for its 2013 Annual Meeting of Stockholders held on June 12, and its Current Report on Form 8-K filed on June 13, 2013, Progenics' Board of Directors previously approved, subject to stockholder approval, and its stockholders approved at the Annual Meeting, an amendment to the Company's 2005 Stock Incentive Plan to increase the number of shares of common stock available for issuance under the Plan from 8,450,000 to 10,450,000. A copy of the Plan is filed as Exhibit 10.1 hereto and is incorporated into this Item 5.02 by this reference.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
|
(d)
|
Exhibits
|
|
Exhibit No.
|
Description
|
|
10.1
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
PROGENICS PHARMACEUTICALS, INC.
|
|
|
|
By:
|
/s/ ANGELO W. LOVALLO, JR.
|
|
|
|
Angelo W. Lovallo, Jr.
|
|
|
|
Vice President, Finance & Treasurer
|
|
|
|
(Principal Financial and Accounting Officer)
|
Date: June 17, 2013